Izokibep's failure makes M&A slightly more likely but needs to materialize in Q1 to justify the valuation
With the recent surprise fail by competitor Acelyrin with izokibep in a phase 2b/3 in HS, we see a more open field for MoonLake's sonelokimab although it does potentially invalidate the small size advantage touted. That said, we believe it was a trial failing the drug situation with izokibep so the
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.